Medication info
Jardis Duo Tablets 5/1000 mg (Empagliflozin, Metformin)

Jardis Duo Tablets 5/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Brownish yellow, round, biconvex, film-coated tablets
Packaging
10 tablets/box [10 tablets/PTP×1], 30 tablets/bottle, 60 tablets/box [10 tablets/PTP×6], 60 tablets/bottle
Approval status
Active

MFDS item code 202201351 · Approved 2022.04.04 · Insurance code 657808290

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). Elderly Patients In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular events
View approved original text

This medication is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In particular, the combination of empagliflozin and metformin aids in blood sugar management. Moreover, it is important to note the heightened risk of cardiovascular events in patients with cardiovascular disease who do not achieve adequate blood sugar control. This medication is effective in improving diabetes management and blood sugar control.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). Elderly Patients In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Precautions

This medication is used for the treatment of diabetes, utilizing two components to achieve blood sugar control. Caution is advised as a rare side effect known as severe lactic acidosis may occur while using this medication. Lactic acidosis can lead to an excessive accumulation of lactate in the body, posing life-threatening risks. Additionally, concomitant administration with insulin or sulfonylureas may increase the risk of hypoglycemia or dangerously low blood sugar levels, necessitating special care. This medication should not be used in patients with moderate to severe renal impairment or those with certain acute conditions, such as dehydration, severe infections, or heart function failure. It is advised to temporarily discontinue this medication before and after tests involving radiocontrast iodine agents and resume only after renal function has been confirmed as normal. Pregnant or breastfeeding women should refrain from using this medication and, especially, women with potential for pregnancy should avoid it. During treatment, it is fundamental to regularly monitor renal function to ensure the drug is used safely. Reported side effects include hypoglycemia, urinary tract infections, genital infections, increased urination, gastrointestinal disturbances (nausea, vomiting, diarrhea), abnormal liver function, etc. In particular, this medication may cause fluid loss; therefore, elderly patients or those at risk of dehydration should be particularly cautious while using it. When taking this medication alongside other drugs, possible interactions might occur, so all medications being used should be disclosed to healthcare providers. In case of an overdose, blood dialysis may be necessary, confirming the importance of adhering strictly to the prescribed dosage. This medication is not recommended for children, and dosage adjustment may be needed in elderly patients based on renal function. Lastly, immediate consultation with healthcare providers is essential if symptoms such as fever, genital discomfort or swelling, or skin rashes occur during treatment.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • nausea
  • vomiting
Show 181 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • urosepsis
  • pyelonephritis
  • vulvovaginal candidiasis
  • vulvitis
  • balanitis
  • weight loss
  • constipation
  • gastritis
  • dry mouth
  • gastrointestinal disturbance
  • oral discomfort
  • salivary gland pain
  • cerebral infarction
  • headache
  • sensory loss
  • orthostatic dizziness
  • dizziness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • urinary stones
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • epistaxis
  • asthma
  • exertional dyspnea
  • moist cough
  • allergic rhinitis
  • residual phlegm
  • insomnia
  • anxiety
  • depression
  • sleep disorder
  • otalgia
  • orthostatic vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • diabetic foot
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • cough
  • dyspnea
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular disorder
  • peripheral arterial occlusive disease
  • cervical inflammation
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • vaginal discharge
  • hyperglycemia
  • hyponatremia
  • dyslipidemia
  • decreased appetite
  • thirst
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • cough
  • dyspnea
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular disorder
  • peripheral arterial occlusive disease
  • cervical inflammation
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • vaginal discharge

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius to ensure the safety and effectiveness of the medication.

Appearance and packaging

Appearance

Brownish yellow, round, biconvex, film-coated tablets

Package unit

10 tablets/box [10 tablets/PTP×1], 30 tablets/bottle, 60 tablets/box [10 tablets/PTP×6], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.